The Pharma Data

JUNE 7, 2023

. “Complementing in-house expertise with external collaboration continues to be a priority in areas of high unmet medical need where insufficient, or no treatment options are currently available,” said Friedemann Janus, acting Head of Business Development and Licensing/Open Innovation, Pharmaceuticals Division, Bayer.

Gene Therapy 40

Gene Therapy Gene Gene Editing RNA 40

The Pharma Data

NOVEMBER 3, 2020

LogicBio’s proprietary genome editing technology platform, GeneRide, enables the site-specific integration of a therapeutic transgene without nucleases or exogenous promoters by harnessing the native process of homologous recombination. LogicBio is headquartered in Lexington, Mass. For more information, please visit www.logicbio.com.

Clinical Trials 52

Clinical Trials Clinical Trials Gene Editing Genome 52

Drug Discovery World

APRIL 17, 2024

JMB: There’s no doubt that it’s been a tough environment to raise funds, and the market has only worsened in 2023. We can envision it this way: at a given genomic site, some TFs are engaged in activating the gene, while others are engaged in suppressing it. DS: You raised $100 million in a Series B financing round in 2022.

Gene Expression 59

Gene Expression Gene Genetic Disease RNA 59

pharmaphorum

MARCH 8, 2022

After a few years, I decided I wanted to move into the commercial side of the business, so I completed an MBA and went on to hold various positions in Corporate Business Development, Life Science and Healthcare. I have been general manager for Merck Healthcare UK & Ireland since 2020.

Life Science 98

Life Science Engineer Scientist Doctors 98

Drug Discovery World

APRIL 29, 2024

Dr Andrew Lewis, Chief Scientific Officer; Kieron Hall, Chief Marketing Officer; and Eric Bironneau, Chief Business Officer, Quotient Sciences: Lewis has held various scientific leadership positions at Quotient and was previously Director of Novel Drug Delivery Technologies at Ipsen.

Drugs 52

Drugs Sales Gene Therapy Life Science 52

The Pharma Data

JANUARY 4, 2021

Longwood has a robust research department with 7 post doctorates conducting research in molecular biology, microbiology, genomics, cancer biology, and immunology and publishing over 75 publications in different scientific journals in the past 5 years. Barber also serves on Kiromic’s Scientific Advisory Board. About Longwood University.

In-Vivo 40

In-Vivo Development Big Data Immune Response 40

Drug Discovery World

SEPTEMBER 6, 2022

Indeed, the growth of the cell and gene therapy market, coupled with the demand that the pandemic placed on manufacturing capacity, means the industry faces shortages of these crucial materials. The challenge for the market then, according to Boissel, is how much can a payor afford to pay upfront? .

Gene Therapy 52

Gene Therapy Gene Manufacturing Medicine 52

The Pharma Data

OCTOBER 14, 2020

They offer access to an intact genome which allows whole genome sequencing without a background. We are looking forward to exploring business development opportunities with innovative companies in these two fields of use who are interested in a technology platform offering a real competitive advantage” said Savran.

Clinical Trials 40

Clinical Trials Clinical Trials Trials Genome 40

The Pharma Data

OCTOBER 26, 2020

50%) with no EGFR or ALK genomic tumor aberrations. L1 expression with no EGFR or ALK genomic tumor aberrations at the IASLC 2020 North America Conference on Lung Cancer (NACLC). The FDA has granted V181, the company’s investigational dengue vaccine in Phase 1 development, Fast Track designation. In the U.S.,

Sales 40

Sales Vaccination Vaccine Production 40

The Pharma Data

AUGUST 6, 2020

Marketing, selling and administrative expenses increased 51% to $1.6 Cash, cash equivalents and marketable debt securities were $22.2 FDA for the first-line treatment of adult patients with metastatic or recurrent non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations. Research and development expense.

Production 52

Production Branding Marketing Licensing 52

The Pharma Data

NOVEMBER 15, 2020

Prior to Celgene, she held leadership roles in marketing, sales and new business development from 2002 to 2011 at Johnson & Johnson. Most recently, she was a senior executive at Celgene Corporation, where she led corporate strategy from 2012 to 2017. Before that, Ms.

Clinical Trials 40

Clinical Trials Clinical Trials Production Trials 40

Drug Discovery World

NOVEMBER 8, 2023

Kathrin Herbst, PhD, Director of Science & Business Development, Lightcast, on: ‘A new era of single-cell functional profiling for drug discovery’. Marketing Product Manager, Product, NanoTemper Technologies. CTO, Sphere Fluidics Limited, on: “Picodroplets for cell line engineering: a novel automation approach”.

Antibody 65

Antibody Engineer Protein Scientist 65

Pharmaceutical Technology

MARCH 20, 2023

Investors are approaching the biotech public markets with caution. Disruption has been catalysed by China’s tough handling of the Covid-19 pandemic, with capital flowing into tech-forward markets like Singapore and helping a wave of innovation to spread across the region. One significant growth area is the rise of genomics.

Gene Therapy 225

Gene Therapy Genome Genomics Gene 225